BUY Aurobindo Pharma — Ashish Kyal, Waves Strategy Advisors
byAshish Kyal, Waves Strategy AdvisorsHorizon: NA (inferred Swing (≤2wk))2 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD
NewsEt-Markets·31 Aug · 2d ago
Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.
NSE · Press Release·31 Aug · 2d ago
Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus in the US. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in
BSE · Company Update·31 Aug · 2d ago
2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·1 Sept · 2d ago
Aurobindo Pharma Share Price Gains As USFDA Concludes Inspection At Subsidiary Lannett's Unit
NewsNdtv-Profit·24 Aug · 1w ago
Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.
BSE · Company Update·1 Sept · yesterday
Aurobindo Pharma’s API plant gets three US FDA observations after inspection
NewsCnbc-Tv18·28 Aug · 5d ago
Here's why these four pharma stocks are in focus today
NewsCnbc-Tv18·24 Aug · 1w ago
USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra
NewsNdtv-Profit·28 Aug · 5d ago
Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA
NewsLivemint·24 Aug · 1w ago
1 advisor has an active short-term SELL call on this stock
Advisor consensus · adjacent horizon·6 Aug · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Aurobindo Pharma
- SELL — Sahaj Agrawal, Kotak Securities21 Oct 2026 · ~2 weeks · target ₹1,540 · Active
- BUY — Arun Kumar Mantri12 Oct 2026 · ~2 weeks · target ₹1,745 · SL hit
- BUY — Ajit Mishra, Religare12 Oct 2026 · ~2 weeks · target ₹1,820 · SL hit
- BUY — Manas Jaiswal12 Oct 2026 · ~2 weeks · target ₹1,750 · SL hit
- BUY — Rupak De, LKP Securities9 Oct 2026 · ~2 weeks · target ₹1,800 · SL hit
More from Ashish Kyal, Waves Strategy Advisors
- BUY Punjab National Bank14 Oct 2026 · Next day · target ₹125 · SL hit
- BUY L&T Technology Services14 Oct 2026 · ~1 year · target ₹3,800 · Target hit
- BUY Redington14 Oct 2026 · ~2 weeks · target ₹426 · SL hit
- BUY Info Edge (India)9 Oct 2026 · ~2 weeks · target ₹1,280 · Active
- BUY Colgate Palmolive (India)9 Oct 2026 · ~2 weeks · target ₹1,950 · SL hit

